Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims at conducting a first-in-human clinical trial in rGBM using SonALAsense's innovative Phase 0 approach to rapidly assess safety, and biological and clinical efficacy of aminolevulinic acid (ALA SDT).
Lead Product(s): Aminolevulinic Acid HCl
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: SonALAsense
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 14, 2020